Medical treatment of uterocutaneous fistula with gonadotropin-releasing hormone agonist administration

Obstet Gynecol. 2008 Feb;111(2 Pt 2):526-8. doi: 10.1097/01.AOG.0000281670.94265.5c.


Background: Uterocutaneous fistula is a rare complication of uterine surgery. All published cases have been surgically treated with hysterectomy and excision of the fistulous tract. We report a case of uterocutaneous fistula that was successfully treated with gonadotropin-releasing hormone agonist administration.

Case: A 25-year-old woman reported bloody discharge during her periods from a previous Pfannenstiel incision. A fistulous tract leading from the incision scar to the uterus was diagnosed. Leuprolide acetate depot was administered twice subcutaneously at a dose of 11.25 mg. The fistulous tract closed spontaneously, and the patient was symptom free thereafter.

Conclusion: Medical treatment with gonadotropin-releasing hormone agonists should be considered before resorting to surgery for treatment of uterocutaneous fistulae.

Publication types

  • Case Reports

MeSH terms

  • Adult
  • Antineoplastic Agents, Hormonal / therapeutic use*
  • Cesarean Section / adverse effects
  • Cutaneous Fistula / diagnosis
  • Cutaneous Fistula / drug therapy*
  • Cutaneous Fistula / etiology
  • Female
  • Gonadotropin-Releasing Hormone / agonists*
  • Humans
  • Leuprolide / therapeutic use*
  • Uterine Diseases / diagnosis
  • Uterine Diseases / drug therapy*
  • Uterine Diseases / etiology


  • Antineoplastic Agents, Hormonal
  • Gonadotropin-Releasing Hormone
  • Leuprolide